Hydrogen Therapy Shows Promise for Lupus Heart Complications
- Authors
- Chin Liu, Jeng-Wei Lu, Chun-Hsien Wu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2026
- DOI
- 10.21873/invivo.14220
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Systemic Lupus Erythematosus
- Body System
- Cardiovascular
TL;DR
Hydrogen capsule therapy improved immune balance in a lupus patient with pulmonary hypertension, suggesting potential support for autoimmune-related vascular disease.
Key Finding
In one lupus patient with lung complications, hydrogen capsule therapy was associated with changes in immune cell markers suggesting reduced immune activation, including decreased populations of certain B-cell types.
Summary
This case report describes one patient with lupus (an autoimmune disease) who also had high blood pressure in the lungs. She received hydrogen capsules as an additional treatment. Blood tests showed changes in immune cells that suggest the hydrogen may have helped calm down the overactive immune response. However, this is just one patient's experience, not a controlled study.
Practical Takeaway
This is a single case report rather than a controlled clinical trial, so it provides only preliminary, anecdotal evidence. While the immune cell changes are interesting, they don't prove hydrogen therapy is effective for lupus-related lung disease. Much larger and more rigorous studies would be needed before any health recommendations could be made.
Abstract
Background/aim: Pulmonary arterial hypertension (PAH) is a significant and challenging complication for patients with systemic lupus erythematosus (SLE). It is thought to arise from immune dysregulation and vascular remodeling, ultimately leading to progressive right heart failure. Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, may modulate the immune responses seen in autoimmune diseases. This case report details the use of adjuvant hydrogen capsule therapy in a patient with SLE with PAH, suggesting its potential as a novel approach for this difficult clinical condition. Case report: A 42-year-old Taiwanese woman with SLE-PAH received hydrogen capsule therapy, during which serial immunophenotyping revealed dynamic changes in suppressive markers including programmed cell death protein 1 (PD1) and Fas cell surface death receptor (FAS), as well as regulatory T- and B-cell subsets. Notably, the populations of double negative and class-switched memory B-cells decreased during therapy, suggesting durable immune suppression. These results support the effect of hydrogen capsule therapy in achieving immune tolerance and inflammation modulation. Conclusion: This case study suggests that molecular hydrogen therapy may be a promising treatment for patients with SLE-PAH, particularly due to its immunomodulatory effects.